PHOENIX, July 18, 2018 (GLOBE NEWSWIRE) -- William Hartman, CEO of Premier Biomedical Inc. (OTC PINK:BIEI) ("the Company") joined Everett Jolly on Uptick Newswire’s “Stock Day” podcast.
Premier Biomedical currently consists of two groups: The Biologics Group deals fundamentally with the treatment of disease, both extra-corporeally and via immunotherapy, while the second group, PainReliefMeds.Com, has developed a series of hemp oil CBD topical pain relief products (www.painreliefmeds.com).
“William welcome back to the show,” said Jolly. “Can you tell me about where the company is heading with its R&D and also about the company’s recent stock reverse split.”
“We are focused on our revenue-producing products in order to keep our R&D efforts moving. Our pain relief topical products are THC free,” said Hartman. “We have Certificates of Analysis for the purity of our products. We are very excited about our future. We have eight total topical pain products with more CBD than the competition and a new Extra Strength Pain-Ex II™ line of products with some products at 500 mg of CBD. We are also looking at an ingestible form in the near future.”
For more details on the company, click the link below to hear the rest of the interview. You will also hear more about the company’s international expansion goals, participation in the Sorinex Summer Strong event in May, and efforts to combat opioid addiction.
https://upticknewswire.com/featured-interview...qb-biei-8/
About Premier Biomedical
Premier Biomedical, Inc. has acquired exclusive licenses for patent-pending medications/ medical procedures to develop cures for a significant number of the most debilitating and often fatal illnesses affecting mankind: Amyotrophic Lateral Sclerosis (ALS), Traumatic Brain Injury (TBI), Multiple Sclerosis (MS), Clinical Depression, Alzheimer’s Disease, Blood Sepsis, Atherosclerosis and Cancer. We have developed an aggressive timetable to advance the development of these breakthrough technologies though laboratory, hospital, and clinical trials. We have initiated the development of potential patient trial application lists. We have a management team with extensive experience and contacts in the medical/pharmaceutical fields as well as demonstrated track record of launching new business ventures in a competitive environment. Our extensive contacts in the medical/pharmaceutical industries will ensure that new developments will achieve maximum visibility and exposure to the market. Transparency and accountability will continue to be ensured via regular issuance of technical progress reports, financials, and investor relations reports to maintain investor enthusiasm.
Premier Biomedical, Inc., a Nevada corporation, is a fully reporting issuer under the Securities Exchange Act of 1934, listed under “BIEI” on the OTC-BB Index.
Safe Harbor Statement
Certain statements contained herein are “forward-looking statements,” (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements and assumptions made in this news release constitute forward-looking statements; the company makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, and other estimates made by management. Actual results could differ from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.
About Uptick Newswire
Uptick Newswire is a private company reaching out to the masses keeping investors and shareholders up to date on company news and bringing transparency to the undervalued, undersold, micro-cap stocks of the market and is the sole producer of the Uptick Network “Stock Day” Podcast. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire and has recently launched the Video Interview Studio located in Phoenix, Arizona.
Contact Information: William A. Hartman President & CEO Premier Biomedical Inc. (724) 633-7033 w.hartman@premierbiomedical.com www.premierbiomedical.com
